91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
on supply-chain strategies to help mitigate vulnerabilities in both autologous and allogeneic cell therapy manufacturing.
-
conducted by 91黑料's Health Economics team and Bristol-Myers Squibb evaluates a cost-effective new treatment for melanoma patients in Japan.
-
that examines how innovation, from the development of targeted therapies to a revolution in clinical trial designs, puts an emphasis on patient centricity.
-
91黑料 experts Andreas Dreps and Martin Lachs share their thoughts on the future of cancer research and the importance of staying adaptive in PharmaPhorum's '' magazine.
-
This article featured in ClinicalOmics '' (pages 48 & 49) considers how cell and gene therapies are playing an increasingly important role in treating oncology patients.
-
A panel discussion providing .
-
Scientific Affairs Manager Candice Willey provides commentary on the difficulties of using CTCs in diagnostic testing despite their promise, the emergence of new CTC technologies to improve tumor sample accessibility, and the benefits of integrating CTC information into clinical trial decisions.
-
Transforming cell and gene therapy trial design and execution
With over 400 dedicated Cell and Gene Therapy professionals globally, 91黑料 has developed tools and best practices to transform CGT trial design and execution.
